Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 4/20 | 0.54 |
| ▸ | TK2 | O00142 | 1/20 | 0.54 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19486372 | 0.89 | TK1 (0.62) | TK1RNASE1LMNAALBPKM | |
| SCHEMBL31685425 | 0.83 | TK1 (0.54) | TK1TK2RNASE1LMNASMN1; SMN2 | |
| SCHEMBL3388279 | 0.83 | TK1 (0.62) | TK1TK2RNASE1LMNASMN1; SMN2 | |
| SCHEMBL9780588 | 0.83 | TK1 (0.62) | TK1TK2RNASE1LMNASMN1; SMN2 | |
| SCHEMBL3388282 | 0.83 | TK1 (0.62) | TK1TK2RNASE1LMNASMN1; SMN2 | |
| SCHEMBL9780593 | 0.83 | TK1 (0.62) | TK1TK2RNASE1LMNASMN1; SMN2 | |
| SCHEMBL3388209 | 0.83 | TK1 (0.62) | TK1TK2RNASE1LMNASMN1; SMN2 | |
| SCHEMBL10594581 | 0.81 | RNASE1 (0.59) | TK1TK2RNASE1LMNASMN1; SMN2 | |
| SCHEMBL10594576 | 0.81 | RNASE1 (0.59) | TK1TK2RNASE1LMNASMN1; SMN2 | |
| Edoxudine SCHEMBL11345587 | 0.80 | TK1 (0.78) | TK1TK2LMNASMN1; SMN2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732344-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2017-08-15 | — | — | US | disclosed |